SukumarNagendranMD

Physician

Dr. Nagendran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1434 W Port Au Prince Ln
Phoenix, AZ 85023
Phone+1 602-795-5820

Fax+1 602-942-7628

Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

PubMed

128 citations
Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy
Linda Lowes, Lindsay N. Alfano, W. David Arnold, Richard Shell, Thomas W. Prior
Pediatric Neurology. 2019-09-01
109 citations
AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
Samiah Al-Zaidy, Stephen J. Kolb, Linda Lowes, Lindsay N. Alfano, Richard Shell
Journal of Neuromuscular Diseases. 2019-01-01
5 citations
Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.
Julio Rosenstock, Eric Hernandez-Triana, Yehuda Handelsman, Soamnauth Misir, Michael R. Jones
Postgraduate Medicine. 2012-07-01

Deerfield Unveils Jaguar Gene Therapy with 4 Preclinical Programs and Access to MoreFebruary 25th, 2021
Neurogene Appoints Industry Leaders Dr. Sukumar Nagendran and Dr. Serge Stankovic to Board of DirectorsFebruary 27th, 2019
AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating ResultsMarch 17th, 2017
Join now to see all